2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2016

9:00AM-11:00AM: Abstract Number: 1405

Quality Measures in High Priority Rheumatologic Diseases: A Systematic Literature Review and Analysis

Quality Measures and Quality of Care - Poster II

9:00AM-11:00AM: Abstract Number: 1706

Quality of Life at Baseline in Early Psoriatic Arthritis Related to Disease Domains

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1059

Quality of Life in Patients with Antiphospholipid Syndrome Is Related to Disease Burden and Anticoagulant Therapy

Antiphospholipid Syndrome - Poster I

9:00AM-11:00AM: Abstract Number: 1296

Quantitative Measurements of Cartilage, Osteophyte, and Bone Marrow Lesion Volume in Knee Osteoarthritis

Imaging of Rheumatic Diseases - Poster II: XR/CT/PET/MRI

9:00AM-11:00AM: Abstract Number: 1520

RA Flare after Total Hip and Total Knee Arthroplasty: Preliminary Outcomes at 1 Year

Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

9:00AM-11:00AM: Abstract Number: 1709

Randomized, Double-Blind Study Comparing Chs-0214 with Etanercept (Enbrel) in Patients with Psoriasis and Psoriatic Arthritis

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1699

RAPID3 Near Remission Shows Good Agreement with Minimal Disease Activity Criteria in Psoriatic Arthritis

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1242

Rate of Hospitalization for Heart Failure Is Lower in Patients with Controlled Gout Versus Uncontrolled Gout

Health Services Research - Poster II

9:00AM-11:00AM: Abstract Number: 1868

Rates and Predictors of Physical Therapy and Occupational Therapy Utilization in Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Study

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster II

9:00AM-11:00AM: Abstract Number: 1637

Real-World Use of Tofacitinib in Rheumatoid Arthritis: Data from the Swiss Clinical Quality Management RA Registry

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

9:00AM-11:00AM: Abstract Number: 1068

Recurrence of Thrombosis Despite Negativization of Antiphospholipid Antibodies in Primary Antiphospholipid Syndrome. a Follow-up to 5 Years

Antiphospholipid Syndrome - Poster I

9:00AM-11:00AM: Abstract Number: 1146

Reducing Imaging Tests for Low Back Pain: Can Patients Choose Wisely?

Education - Poster

9:00AM-11:00AM: Abstract Number: 1395

Regional Brain Gray Matter Volume Loss in Children and Adolescents with SLE

Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster II: Myositis, Systemic Lupus Erythematosus, Sjögren's Syndrome

9:00AM-11:00AM: Abstract Number: 1131

Regulation of Rheumatoid Arthritis Synovial Fibroblast Cytokine Production By Inhibitor of DNA Binding-1 Via Crispr/Cas9 Transfection

Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis - Poster I

9:00AM-11:00AM: Abstract Number: 1450

Regulatory Mechanisms of Mesenchymal Stem Cell Transplantation on Systemic Osteoporosis in Collagen-Induced Arthritis Mice

Rheumatoid Arthritis – Animal Models - Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].